Dual-Antigen-Targeting T Cell Immunotherapies in MM: Circumventing Tumor Heterogeneity and Preventing Antigen Escape

Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for >1 antigen are effective in advanced multiple myeloma; however, at this time, none of the dual-targeting CAR T-cell products have been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel.